Brachytherapy

Publication Title: 
Cancer

BACKGROUND: Among patients with well differentiated papillary thyroid carcinoma who generally have an excellent prognosis and a near-normal lifespan, there exist subsets of patients who have significant risk for morbidity and mortality from this disease. It is important to define the patterns of disease progression and the clinical outcome of such patients to develop effective surveillance and treatment strategies.

Author(s): 
Vassilopoulou-Sellin, R.
Schultz, P. N.
Haynie, T. P.
Publication Title: 
International Journal of Radiation Oncology, Biology, Physics

PURPOSE: To investigate the incidence of and variables associated with clinically evident fat necrosis in women treated on a protocol of high-dose-rate (HDR) brachytherapy alone without external-beam whole-breast irradiation for early-stage breast carcinoma. METHODS AND MATERIALS: From 6/1997 until 8/1999, 30 women diagnosed with Stage I or II breast carcinoma underwent surgical excision and postoperative irradiation via HDR brachytherapy implant as part of a multi-institutional clinical Phase I/II protocol.

Author(s): 
Wazer, D. E.
Lowther, D.
Boyle, T.
Ulin, K.
Neuschatz, A.
Ruthazer, R.
DiPetrillo, T. A.
Publication Title: 
International Journal of Radiation Oncology, Biology, Physics

PURPOSE: To investigate the feasibility, toxicity, cosmetic outcome, and local control of high-dose-rate (HDR) brachytherapy alone without whole breast external beam irradiation for early-stage breast carcinoma. METHODS AND MATERIALS: Between June 1997 and August 1999, 32 women diagnosed with a total of 33 AJCC Stage I/II breast carcinomas underwent surgical breast excision and postoperative irradiation using HDR brachytherapy interstitial implantation as part of a multi-institutional clinical Phase I/II protocol.

Author(s): 
Wazer, David E.
Berle, Lisa
Graham, Roger
Chung, Maureen
Rothschild, Janice
Graves, Theresa
Cady, Blake
Ulin, Kenneth
Ruthazer, Robin
DiPetrillo, Thomas A.
Publication Title: 
Cancer

BACKGROUND: Alternative medicine therapies are estimated to be used by 7-64% of cancer patients but up to 72% do not inform their physician. To the authors' knowledge little useful information is available regarding the prevalence of alternative medicine use by patients with prostate carcinoma. Thus, the authors attempted to evaluate the prevalence of alternative medicine use by prostate carcinoma patients treated with curative intent by either radical prostatectomy, brachytherapy alone, or a combination of brachytherapy and external radiation therapy.

Author(s): 
Lippert, M. C.
McClain, R.
Boyd, J. C.
Theodorescu, D.
Publication Title: 
Revue Médicale De La Suisse Romande

Patient aged 49 who developed hypothyroidism after receiving 1131 for relapsing Graves' disease after treatment with propylthiouracil followed by homeopathy. Substitution with thyroxine (0.05 mg/day) was prescribed. Depressed by the perspective of a life long treatment, the patient swallowed 400 pills (20 mg). The evolution was uncomplicated after betablockers administration at hospital. One year later she became euthyroid without further medication. The occurrence of transient hypothyroidism after curitherapy is discussed.

Author(s): 
Martin-du Pan, R. C.
Publication Title: 
HNO

Primary malignant tumors of the orbit and the orbital adnexal area are rare, variform and in the majority of cases need an interdisciplinary treatment. According to tumor entity, tumor localization, and tumor extent the complete spectrum of radiotherapeutic therapy options is necessary. In the majority of malignant tumors, such as those of the eyelids, lachrymal glands, orbit, metastases, sarcoma or lymphoma, radiotherapy is used as a high energy therapy by means of medical linear accelerators as so-called teletherapy.

Author(s): 
Kuhnt, T.
Janich, M.
Subscribe to RSS - Brachytherapy